Does somatostatin-14 have an impact on gastric fistula after laparoscopic sleeve gastrectomy?

Abstract

The main complications following laparoscopic sleeve gastrectomy (LSG) is gastric fistula (GF). Gastric fistula is a rare but serious complication (affecting 2 % of LSGs). Somatostatin-14 and its analogs are mainly used in the prevention and curative treatment of digestive fistulas. These compounds inhibit secretions in the pancreas, stomach, and small intestine. Treatment with somatostatin-14 increases the spontaneous closure rate and reduces the closure time of postoperative digestive fistulas. However, the impact of somatostatin-14 on GF after LSG has not been studied. We report on a prospective, non-randomized, single-center, case-matched study of patients receiving somatostatin-14 after a post-LSG GF was discovered. Our results suggest that use of somatostatin-14 is associated with a shorter length of hospital stay and (perhaps) a shorter treatment period.

• Authors: Lionel Rebibo, Flavien Prevot, Abdennaceur Dhahri, Jean-Marc Regimbeau
• Journal: Obesity surgery (Obes Surg) Vol. 25 Issue 2 Pg. 377-80 (Feb 2015) ISSN: 1708-0428 [Electronic] United States
• PMID: 25381116 (Publication Type: Journal Article)

Chemical References

• Somatostatin

Topics

• Adult
• Case-Control Studies
• Female
• Gastrectomy (adverse effects, methods)
• Gastric Fistula (epidemiology, etiology, prevention & control)
• Humans
• Laparoscopy (adverse effects, methods)
• Length of Stay
• Male
• Middle Aged
• Obesity, Morbid (drug therapy, epidemiology, surgery)
• Postoperative Complications (epidemiology, etiology, prevention & control)
• Prospective Studies
• Retrospective Studies
• Somatostatin (therapeutic use)
• Young Adult